Sim&Cure key facts
as of Oct 2026- Developer of a patient-specific device designed to secure the treatment of a cerebral aneurysm.
- Sim&Cure is valued at approximately $48.7M as of Oct 2026 (last reported valuation).
- It has raised $21.1M; the latest was Equity Crowdfunding ($840K) in Apr 2025.
- Notable investors include Elaia Partners, IRDI Capital Investissement, SWEN Capital Partners, Sofilaro, Alexis Frentz — 13 tracked in total.
- Status: Privately Held (backing).
Sim&Cure's last reported valuation, Nov 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Sim&Cure: the Monday email on marks, rounds and moves
Sim&Cure funding rounds
No funding rounds for Sim&Cure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Sim&Cure
13+Sim&Cure valuation
Sim&Cure's last reported valuation was $48.7 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.
Sim&Cure investors
13 investors are on record for Sim&Cure, including Elaia Partners, IRDI Capital Investissement, SWEN Capital Partners and Sofilaro.
About Sim&Cure
Developer of a patient-specific device designed to secure the treatment of a cerebral aneurysm. The company's device is fast and has optimal sizing, virtually evaluates the final position of different sizes and shapes of intracranial implants and secures the treatment, enabling neurologists to treat patients with neurovascular disorders.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2013
- Employees
- 65
- Website
- sim-and-cure.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.